Brief Reports Open Access
Copyright ©2005 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Feb 28, 2005; 11(8): 1204-1209
Published online Feb 28, 2005. doi: 10.3748/wjg.v11.i8.1204
Protective effect of Weikang decoction and partial ingredients on model rat with gastric mucosa ulcer
Tuo-Ying Fan, Qing-Qing Feng, Qun Fan, Chun-An Li, Xue-Lian Bai, 94 Hospital of PLA, Nanchang 330002, Jiangxi Province, China
Chun-Rong Jia, People’s Hospital of Wuhan University, Wuhan 430060, Hubei Province, China
Qun Fan, Shenzhen Donghu Hospital, Shenzhen 518020, Guangdong Province, China
Author contributions: All authors contributed equally to the work.
Supported by the Education Commission of Hubei Province, No. (1996)028
Correspondence to: Dr. Qun Fan, Shenzhen Donghu Hospital, Shenzhen 518020, Guangdong Province, China. fqng1008@163.com
Telephone: +86-755-25634729 Fax: +86-755-25604034
Received: March 20, 2004
Revised: March 23, 2004
Accepted: June 11, 2004
Published online: February 28, 2005

Abstract

AIM: To investigate the protective mechanisms of Weikang (WK) decoction on gastric mucosae.

METHODS: Ninety rats were randomly divided into nine groups of 10 each, namely group, model group, group with large WK dosage, group with medium WK dosage, group with small WK dosage, group with herbs of jianpiyiqi (strengthening the spleen and replenishing qi), group with herbs of yangxuehuoxue (invigorating the circulation of and nourishing the blood), group with herbs of qingrejiedu (clearing away the heat-evils and toxic materials), group with colloidal bismuth pectin (CBP) capsules. According to the method adopted by Yang Xuesong, except normal control group, chronic gastric ulcer was induced with 100% acetic acid. On the sixth day after moldmaking, WK decoction was administered, respectively at doses of 20, 10 and 5 g/kg to rats of the WK groups, or the groups with herbs of jianpiyiqi, yangxuehuoxue and qingrejiedu, 10 mL/kg was separately administered to each group every day. For the group with CBP capsules, medicine was dissolved with water and doses 15 times of human therapeutic dose were administered (10 mL/kg solution containing 0.35% CBP). Rats of other groups were fed with physiological saline (10 mL/kg every day). Administration lasted for 16 d. Rats were killed on d 22 after mold making to observe changes of gastric mucosa. The mucus thickness of gastric mucosa surface was measured. Levels of epidermal growth factor (EGF) in gastric juice, nitric oxide (NO) in gastric tissue, endothelin (ET) in plasma, superoxide dismutase (SOD) in plasma, malondialdehyde (MDA) in plasma and prostaglandin I2 (PGI2) were examined.

RESULTS: Compared with control group, ulceration was found in gastric mucosa of model group rats. The mucus thickness of gastric mucosa surface, the levels of EGF, NO, 6-K-PGF1α and SOD decreased significantly in the model group (EGF: 0.818±0.18 vs 2.168±0.375, NO: 0.213±0.049 vs 0.601±0.081, 6-K-PGF1α: 59.7±6.3 vs 96.6±8.30, SOD: 128.6±15.0 vs 196.6±35.3, P<0.01), the levels of ET (179.96±37.40 vs 46.64±21.20, P<0.01) and MDA (48.2±4.5 vs 15.7±4.8, P<0.01) increased. Compared with model group, the thickness of regenerative mucosa increased, glandular arrangement was in order, and cystic dilative glands decreased, while the mucus thickness of gastric mucosa surface increased (20 g/kg WK: 51.3±2.9 vs 23.2±8.4, 10 g/kg WK: 43.3±2.9 vs 23.2±8.4, 5 g/kg WK: 36.1±7.2 vs 23.2±8.4, jianpiyiqi: 35.4±5.6 vs 23.2±8.4, yangxuehuoxue: 33.1±8.9 vs 23.2±8.4, qingrejiedu: 31.0±8.0 vs 23.2±8.4 and CBP: 38.2±3.5 vs 23.2±8.4, P<0.05-0.01). The levels of EGF (20 g/kg WK: 1.364±0.12 vs 0.818±0.18, 10 g/kg WK: 1.359±0.24 vs 0.818±0.18, 5 g/kg WK: 1.245±0.31 vs 0.818±0.18, jianpiyiqi: 1.025± 0.45 vs 0.818±0.18, yangxuehuoxue: 1.03±0.29 vs 0.818±0.18, qingrejiedu: 1.02±0.47 vs 0.818±0.18 and CBP: 1.237±0.20 vs 0.818±0.18, P<0.05-0.01), NO (20 g/kg WK: 0.480±0.026 vs 0.213±0.049, 10 g/kg WK: 0.390±0.055 vs 0.213±0.049, 5 g/kg WK: 0.394±0.026 vs 0.213±0.049, jianpiyiqi: 0.393±0.123 vs 0.213±0.049, yangxuehuoxue: 0.463±0.077 vs 0.213±0.049, qingrejiedu: 0.382±0.082 vs 0.213±0.049 and CBP: 0.395±0.053 vs 0.213±0.049, P<0.05-0.01), 6-K-PGF1α (20 g/kg WK: 86.8±7.6 vs 59.7±6.3, 10 g/kg WK: 77.9±7.0 vs 59.7±6.3, 5 g/kg WK: 70.0±5.4 vs 59.7±6.3, jianpiyiqi: 73.5±12.2 vs 59.7±6.3, yangxuehuoxue: 65.1±5.3 vs 59.7±6.3, qingrejiedu: 76.9±14.6 vs 59.7±6.3, and CBP: 93.7±10.7 vs 59.7±6.3, P<0.05-0.01) and SOD (20 g/kg WK: 186.4±19.9 vs 128.6±15.0, 10 g/kg WK: 168.2±21.7 vs 128.6±15.0, 5 g/kg WK: 155.6±21.6 vs 128.6±15.0, jianpiyiqi: 168.0±85.3 vs 128.6±15.0, yangxuehuoxue: 165.0±34.0 vs 128.6±15.0, qingrejiedu: 168.2±24.9 vs 128.6±15.0, and CBP: 156.3±18.1 vs 128.6±15.0, P<0.05-0.01) significantly increased. The levels of ET (20 g/kg WK: 81.30±17.20 vs 179.96±37.40, 10 g/kg WK: 83.40±25.90 vs 179.96±37.40, 5 g/kg WK: 93.87±20.70 vs 179.96±37.40, jianpiyiqi: 130.67±43.66 vs 179.96±37.40, yangxuehuoxue: 115.88±34.09 vs 179.96±37.40, qingrejiedu: 108.22±36.97 vs 179.96±37.40, and CBP: 91.96±19.0 vs 179.96±37.40, P<0.01) and MDA (20 g/kg WK: 21.6±7.4 vs 48.2±4.5, 10 g/kg WK: 32.2±7.3 vs 48.2±4.5, 5 g/kg WK: 34.2±6.2 vs 48.2±4.5, jianpiyiqi: 34.9±13.8 vs 48.2±4.5, yangxuehuoxue: 35.5±16.7 vs 48.2±4.5, qingrejiedu: 42.2±17.6 vs 48.2±4.5, and CBP: 30.1±6.1 vs 48.2±4.5, P<0.05-0.01) obviously decreased. The 20 g/kg WK group was better than 10 g/kg (the mucus thickness: 51.3±2.9 vs 43.3±2.9, NO: 0.480±0.026 vs 0.390±0.055, SOD: 186.4±19.9 vs 168.2±21.7, P<0.01) and 5 g/kg (the mucus thickness: 51.3±2.9 vs 36.1±7.2, NO: 0.480±0.026 vs 0.394±0.026, SOD: 186.4±19.9 vs 155.6±21.6, P<0.01) groups and CBP group (the mucus thickness: 51.3±2.9 vs 38.2±3.5, NO: 0.480±0.026 vs 0.395±0.053, SOD: 186.4±19.9 vs 156.3±18.1, P<0.01) in the mucus thickness, NO and SOD levels and better than 10 g/kg (86.8±7.6 vs 77.9±7.0, P<0.05) and 5 g/kg (86.8±7.6 vs 70.0±5.4, P<0.05) groups in 6-K-PGF1α level, 10 g/kg WK group was better than 5 g/kg WK (the mucus thickness: 43.3±2.9 vs 36.1±7.2, P<0.01, SOD: 168.2±21.7 vs 155.6±21.6, P<0.05) and CBP groups (the mucus thickness: 43.3±2.9 vs 38.2±3.5, P<0.01, SOD: 168.2±21.7 vs 156.3±18.1, P<0.05) in the mucus thickness and SOD level. In compound group, jianpiyiqi group, yangxuehuoxue group, qingrejiedu group, the level of ET was decreased, NO contents were increased in gastric tissue of ulcers in rats.

CONCLUSION: WK decoction and separated recipes have significantly protective effect on ethanol-induced gastric mucosal injury. They can increase the content of EGF in gastric juice, PGI2 SOD in plasma and NO in gastric tissues, thicken the mucus on the gastric mucosa, and decrease the impairing factor MDA, ET in plasma.

Key Words: Gastric mucosa/drug effects; Gastric ulcer; Epidermal growth factor; Nitric oxide



INTRODUCTION

PU is a common disease with a high clinical incidence, which features predicted curative ratio up to 95%, but high relapse rate at about 65-80% one year after withdrawal and up to nearly 100% within two years. Such being the case, treatment of PU and prevention of its relapse still is a problem in the medical field[1-5]. When the gastric mucosa is normal, the gastric wall can prevent digestion in the stomach by the mucus with hydrogen ion’s consistence being 3-4 million times higher than that in the blood. Furthermore, most of the ulcerations are caused by the weakening of the protective ability of mucosa than by the increasing of the attacking factors[6-8]. In recent years, many experts have proved, by virtue of modern approaches, that herbs for strengthening the spleen can remove the damage to gastric mucosa in experiments, and can withstand ulcerations by way of consolidating the barrier of gastric mucus, speeding up the mucosal blood flow, quickening the reproduction of PGI2, and holding back the damage by free radicals[9,10]. Protective effects of traditional Chinese medicine on gastric and intestinal mucosa offer a new method. WK decoction can treat PU and prevent relapse of PU according to clinical research[9-13]. The experiment was carried out to investigate the possible mechanisms and find a new traditional Chinese medical recipe on mucosal protection.

MATERIALS AND METHODS
Materials

Ninety pure wistar rats of either sex (180-250 g), provided by Tongji Medical University Experimental Animal Center, were caged by layer, male and female separated. After 1 wk of feeding, if no unfavorable reaction was inspected, the experiment would begin. Entire herbs consisting of huangqi and pugongying 30 g each, guizhi, zhiganchao and sanqi 6 g each, baishao, yuanhu 15 g each, dahuang 12 g, jianpiyiqi herbs consisting of huangqi 30 g, guizhi and zhiganchao 6 g each, yangxuehuoxue herbs consisting of yuanhu and bansho 15 g each, sanqi 6 g, qingrejiedu herbs consisting of dahuang 12 g and pugongying 30 g. The above herbs were boiled with 400 mL deionized water twice, 30 min each, then, the filtrate was condensed to a concentration of 1 g/mL and was put in a 500-mL glass bottle kept at low temperature. The CBP capsules were produced by Shanxi Ante Biological Pharmaceutical Co., Ltd., 92 Wei Yao Zhun Zi X-47-1.

Methods

Ninety rats were randomly divided into nine groups of 10 each, respectively marked with control group, model group, group with large WK dosage, group with medium WK dosage, group with small WK dosage, jianpiyiqi group, yangxuehuoxue group, qingrejiedu group and group with CBP capsules. According to the method adopted by Yang Xuesong[14], except for the control group, food was withheld for 24 h before modeling while water was allowed. Anesthetized with ether, these rats had their furs cut. Then, along the middle line under the xiphoid process, they were cut open from the belly (the cut was about 2 cm long). The stomach was exposed. Subsequently, filter paper with a diameter of 5 mm immersed in 100% acetic acid was pasted at the serosa at the intersection of antrum phlori and the stomach body twice of 30 s each. After that, new filter paper was used to absorb extra acetic acid on the surface of the stomach. This part was covered with omentum. The stomach was resumed to normal shape. Finally, cuts were sutured by layers, and coated with a layer of diluted ceiba acid for protection purpose. Administration was made to lavage the stomach from the sixth day after modeling. The doses of WK decoction were calculated by extrapolating the human therapeutic dose. Medium dosage was 15 times of human dose (10 mL/kg every d), large dosage was twice as much (20 mL/kg every d) while small dosage of one second (5 mL/kg every d), jianpiyiqi group, yangxuehuoxue group, qingrejiedu group (10 mL/kg every d) was administered to each group, for the group with CBP capsules, medicine was dissolved with water and doses 15 times of human therapeutic dose were administered (10 mL/kg solution containing 0.35% pectin bismuth), rats of other groups were fed with physiological saline (10 mL/kg every d). Administration lasted 16 d. From the 17 d, these rats were fasted for 24 h, water allowed. Before the experiment, the animals received 1 mL physiological saline. Two hours later, they were anesthetized with 1% sodium pentobarbital at a dose of 40-50 mg/kg on the abdomen. Then, the rats were killed by removing their heads. Blood was sampled into two test tubes, one added with 30 μL EDTA disodium and 40 μL aprotinin to measure the concentration of endothelin (ET), and the another with 30 μL EDTA, disodium to measure the thickness of 6-K-PGF1α, MDA and serum superoxide dismutases (SOD). After the stomachs were removed, gastric juice was collected to measure epidermal growth factor (EGF). At the corpus and fundus ventriculus and antrum phlori each, one-third of stomach tissue was sampled, 200 mg in all, to measure the concentration of nitric oxide (NO). And, the ulcerations along the maximum diameter parallel to the longer axis of the stomach were selected and soaked with 10% formalin for 24 h. Pathological sections were taken to observe ulcerations and measure the thickness of mucus on the mucosa surfaces. All the kits for EGF, NO, 6-K-PGF1α, ET, MDA and SOD were provided by Nanjing Juli Biological Co., Ltd. For more details about measurements, please refer to their instruction manuals. Statistical disposition: all data were expressed in mean±SD. Means of specimens were compared by Q test and t test in the analysis of variance.

RESULTS
Overview

When coming around after modeling, the rats began to eat but lost their appetite dramatically. They were not as active as before, their furs and skins were dry and urine volume also decreased. About 5-7 d after modeling, they became active gradually, with appetite getting better, their skins and furs resumed lustrousness and the urine volume also rose. During the experiments, four rats died, three from the jianpiyiqi group, and one from the qingrejiedu group.

Pathological observations

Compared with the control group, rats in the model group suffered from damaged gastric mucosa. Ulcerations were deep into the muscular layer. Additionally, the holes were covered only with little reproduced mucosa, and glands were arranged disorderly, presenting a cystic dilatation. For the rats in the groups respectively with large, medium and small WK dosage, as well as the group with CBP capsules, the mucosa reproduced at the holes of gastric mucosa was thicker than the model group, and the damage area in the muscular layer was smaller. Glands tended to arrange orderly, with those of cystic dilation decreased.

Effect on the thickness of mucus on gastric mucosa

If arranged by the thickness of mucus on the gastric mucosa in ascending order, then the sequence is as follows: model group (P<0.01), group with small WK dosage and group with CBP capsules (P<0.01), group with medium WK dosage (P<0.05), group with large WK dosage (P<0.01), and the control group. There is little difference between the group with small WK dosage and the group with CBP capsules. Moreover, the mucus of the groups with partial ingredients is thicker than the model group (P<0.05-0.01) but thinner than the group with entire ingredients. The results are summarized in Table 1.

Table 1 Thickness of mucus on gastric mucosa surface and the content of EGF in gastric juice (mean±SD).
GroupSpecimensThickness of mucus (mm)EGF (ng/g)
Control1064.1±9.3bd2.168±0.375b
Model1023.2±8.40.818±0.18
WK (20 g/kg)1051.3±2.9bd1.364±0.12a
WK (10 g/kg)1043.3±2.9bc1.359±0.24a
WK (5 g/kg)936.1±7.2b1.245±0.31a
Jianpiyiqi735.4±5.6b1.025±0.45c
Yangxuehuoxue1033.1±8.9b1.03±0.29c
Qingrejiedu931.0±8.01.02±0.47c
CBP capsules1038.2±3.5b1.237±0.20a
Effect on EGF

As shown in Table 1, in terms of the content of EGF in gastric juice, the model group is much lower than the control group (P<0.01), while the groups with large, medium and small WK dosage and the group with CBP capsules, between which there is no dramatic difference, are considerably higher than the model group (P<0.05). In general, groups with partial ingredients are lower than those with entire ingredients (P<0.05) but higher than the model group. The averages of all groups with partial ingredients are very close, with little remarkable difference.

Effect on the content of NO in gastric tissue

As regards the content of NO in gastric tissue, the model group is much lower than the control group (P<0.01), while the groups with large, medium and small WK dosage and the group with CBP capsules are considerably higher than the model group (P<0.05-0.01). The group with large WK dosage and the yangxuehuoxue group are greatly higher than the jianpiyiqi group, qingrejiedu group, group with medium and small WK dosage, the group with CBP capsules. See Table 2.

Table 2 Content of NO in gastric tissue and the content of ET in plasma (mean±SD).
GroupSpecimensNO (mmol/g)ET (pg/mL)
Control100.601±0.081bd46.64±21.20bd
Model100.213±0.049179.96±37.40
WK 20 g/kg100.480±0.026bc81.30±17.20b
WK 10 g/kg100.390±0.055a83.40±25.90b
WK 5 g/kg90.394±0.026a93.87±20.70b
Jianpiyiqi70.393±0.123a130.67±43.66bc
Yangxuehuoxue100.463±0.077bc115.88±34.09bc
Qingrejiedu90.382±0.082a108.22±36.97b
CBP capsules100.395±0.053a91.96±19.0b
Effect on the content of ET in plasma

As shown in Table 2, in regard to the content of ET in plasma, the model group is much higher than the control group (P<0.01), while the groups with herbs and the group with CBP capsules are considerably lower than the model group (P<0.01). For the groups with large, medium and small WK dosage and the group with CBP capsules, there is no dramatic difference among them. The jianpiyiqi group, yangxuehuoxue group, qingrejiedu group are substantially higher than the groups with entire ingredients and with CBP capsules (P<0.05).

Effect on SOD and MDA in plasma

Compared with the control group, the model group is much lower in terms of SOD content (P<0.01), but higher in terms of MDA content (P<0.01). As regards SOD content, the groups with small WK dosage and with CBP capsules are substantially higher than the model group (P<0.05), but much lower than the group with medium WK dosage (P<0.05). The group with large WK dosage is higher than the group with medium WK dosage (P<0.05). In terms of MDA content, the groups with large, medium and small WK dosage and the group with CBP capsules, between which there is no dramatic difference, are hugely lower than the model group (P<0.05-P<0.01). See Table 3.

Table 3 Content of SOD and MDA in plasma of each group (mean±SD).
GroupSpecimensSOD (NU/mL)f MDA (NM/mL)
Control10196.6±35.3bd15.7±4.8bd
Model10128.6±15.048.2±4.5
WK 20 g/kg10186.4±19.9bd21.6±7.4bc
WK 10 g/kg10168.2±21.7ac32.2±7.3a
WK 5 g/kg9155.6±21.6a34.2±6.2a
Jianpiyiqi7168.0±85.3ac34.9±13.8a
Yangxuehuoxue10165.0±34.0ac35.5±16.7a
Qingrejiedu9168.2±24.9ac42.2±17.6ac
CBP capsules10156.3±18.1a30.1±6.1a
Effect on the content of 6-K-PGF1α in plasma

In terms of 6-K-PGF1α content, the model group is much lower than the control group (P<0.01), but higher than the groups with large, medium and small WK dosage and the group with CBP capsules (P<0.05). Between the groups with large, medium and small WK dosage and the group with CBP capsules, there is no dramatic difference (P>0.05), but the group with large WK dosage is greatly higher than the groups with medium and small dosage (P<0.05). See Table 4.

Table 4 Effect of WK on the content of 6-K-PGF1α in plasma in rats (mean±SD).
GroupSpecimens6-K-PGF1a (pg/mL)
Control1096.6±8.3b
Model1059.7±6.3
WK 20 g/kg1086.8±7.6b
WK 10 g/kg1077.9±7.0a
WK 5 g/kg970.0±5.4a
Jianpiyiqi773.5±12.2a
Yangxuehuoxue1065.1±5.3
Qingrejiedu976.9±14.6a
CBP capsules1093.7±10.7b
DISCUSSION

To the present day, major anti-PU medicines aim at fighting against mucosa-attacking factor. Such medicines include H2 receptor antagonism, H+-K+ATP enzyme inhibitor, anti-cholin drugs, Helicobacter pylori (Hp) counteractant[15], etc. When the gastric mucosa is normal, the gastric wall can prevent digestion in the stomach by the mucus with hydrogenion’s consistence 3-4 million times higher than that in the blood. However, when in PU, secretion of gastric acid generally stays low in the normal range, while in duodenal ulcer, the secretion is only 1/3 more than the normal level. Furthermore, not all PU are related with HP, which indicates that most ulcerations are caused by the weakening protective ability of mucosa and not by the increasing of the attacking factor. In clinically traditional Chinese herbs have good effect for PU[16-20]. The WK decoction derives from Jianzhong Astragalus Root Soup, with some herbs added or removed. This recipe mainly functions for strengthening the spleen and replenishing qi, complemented with other effects, such as invigorating the circulation of and nourishing the blood, and clearing away the heat-evils and expelling superficial evils. In recent years, by virtue of modern approaches, many experts have proved, strengthening the spleen can remove the damage to gastric mucosa in experiments, and can withstand ulcerations by way of consolidating the barrier of gastric mucus, speeding up the mucosal blood flow, quickening the reproduction of PGI2, and holding back the damage by free radicals. For mucus, perfect structure is the foundation of its protecting function[21]. It is revealed by our experiments that, regardless of doses, WK in solid state can shrink ulcerations, build up the mucosa barrier, straighten up the arrangement of glands and better the structure. Additionally, dependent on its dosage, WK decoction also can thicken the mucus on the surface of gastric mucosa, which indicates that it can facilitate mucosa to secrete mucus. EGF of the human body can stimulate the mitosis of cells, improve the proliferation and differentiation of epithelium, and speed up the production of DNA and proteins in the gastric mucosa, all of which are of great importance to regenerate and repair the tissue[22-26]. Our experiments show that after modeling the content of EGF of the model group dropped greatly, but that of the groups with large, medium and small WK dosage and with CBP capsules climbed up. Comparatively, large doses of WK exerted more influence on the content of EGF than CBP capsules, which indicates that WK decoction has the function of protecting gastric mucus by enhancing the EGF content and its effect is dependent on dosage. NO protects the stomach by speeding up the circulation of blood in the gastric mucosa. Also, it plays an important role in defending the gastric mucosa as an antioxidant[26,27]. Our experiments reveal that the content of NO in the model group is much lower than that in the control group (P<0.01), indicating a decreased content of NO protective factor in the event of gastric ulceration. The content of NO in the groups with large, medium and small WK dosage and with CBP capsules are dramatically higher than that in the model group. Comparatively, large doses of WK exerted more influence on the content of NO than CBP capsules, which indicates that WK decoction can protect the gastric mucosa by enhancing NO content after treatment but its effect is dependent on dosage. ET may antagonize the effect of NO, leading to an imbalanced NO/ET. As it may slow down the mucosal blood flow, gastric mucosa may be impaired[28-30]. Our experiments show that the content of ET in the model group is much higher than that in the control group, indicating increase of ET in the event of gastric ulceration. The content of NO in the groups with large, medium and small WK dosage and with CBP capsules are dramatically lower than that in the model group, which means that WK decoction can lower the content of ET in plasma by slowing down the production and secretion of ET. In general, to lower ET content and enhance the content of NO can keep NO/ET in balance, maintain normal mucosal blood flow and thus protect the gastric mucosa.

When stimulated by chemicals or in shortage of blood, the gastric and intestinal mucosa will produce tremendous free radicals, which impair mucosa. Through experimental results, we can see that the model group is much higher than the control group (P<0.01) in terms of MDA content but much lower than the latter in terms of SOD content (P<0.01). These data indicate that oxygen-derived free radicals will take part in ulceration and meanwhile oxygen-derived free radical scavengers that have protective function decrease. The groups with large, medium and small WK dosage and with CBP capsules are considerably lower than the model group in terms of MDA content but higher than the latter in terms of SOD content. Furthermore, the groups with medium and small WK dosage are higher than the group with CBP capsules in terms of SOD content (P<0.05), which shows that WK has better effect in increasing SOD contents, removing oxygen-derived free radicals and protecting the gastric mucosa. Its effect is dependent on dosage.

PGI2 can restrain the secretion of gastric acid, enhance the mucosal blood flow and protect the cells and TXB2. However, it has a short half-life period. Within two minutes, it can hydrolyze into stable 6-K-PGF1α. Our experiments show that the content of 6-K-PGF1α in the model group is much lower than that in the control group (P<0.01), indicating that in case of ulceration protective factor 6-K-PGF1α will decrease. But, the groups with large, medium and small WK dosage and with CBP capsules are considerably higher than the model group (P<0.01), which indicates that WK can protect the gastric mucosa and further repair ulcerations by increasing 6-K-PGF1α.

The WK decoction derives from huangqijianzhong decoction[31], with some herbs added or removed. However, huangqijianzhong decoction is mainly used for restoring qi by virtue of warm herbs. In consideration of the pathogenesis of ulcer diseases, such as deficiency of vital energy, blood stasis and tremendous heat toxins[32], we add some herbs for activating blood circulation to dissipate blood stasis[33], such as xuanhu (rhizomacorydalis) and sanqi (pseudoginseng), some herbs dahuang (rhubarbs) and pugongying (dandelion)[34] for clearing away the heat-evils and toxic materials. This recipe mainly functions for strengthening the spleen and replenishing qi, complemented with other effects, such as invigorating the circulation of and nourishing the blood, and clearing away the heat-evils. These experiments show that all the groups with partial ingredients have favorable effect of curing gastric ulcer for rats. These ingredients can increase contents of PGI2, EGF, SOD and NO, thicken the mucus on the gastric mucosa, and decrease the impairing factor MDA and ET. Through comparison, we find out that partial ingredients do not have as good effect as the entirety. In some cases, they show some dramatic statistical difference, while in other cases although there is no such difference, the group with entire ingredients has better figures. Therefore, the entire ingredients have better comprehensive effect in curing ulcerations. All medical herbs have their own substantial foundation supporting their activity and effect in treatment. Since the medicine has so many ingredients that may produce many complicated chemical reactions, its treatment effect is not equal to the aggregate effects of each ingredient. As for its effective substantial foundation, it is to be explored in further researches.

Footnotes

Co-first-authors: Tuo-Ying Fang and Qing-Qing Feng

Co-correspondence: Tuo-Ying Fang

References
1.  Fan Q. Improve the healing quality and treatment of Chinese herbs. Zhongyi Yanjiu. 1995;8:46-47.  [PubMed]  [DOI]  [Cited in This Article: ]
2.  Zhou DQ Treatment of difficult digestive diseases with intergrated traditional and western medicine. Beijing: China Medicine Technical Publishing House 1998; 94-127.  [PubMed]  [DOI]  [Cited in This Article: ]
3.  Fan Q, Zhang HY. Ideology of improving the healing quality of ulcer with Chinese medicine. Zhongguo Zhongxiyi Jiehe Piwei Zazhi. 1996;4:186.  [PubMed]  [DOI]  [Cited in This Article: ]
4.  Liu JP, Wang WZ, Bai JL, Bu T, Zhong QH. Recent circumstance on improving healing quality of peptic ulcer with Chinese medicine. Shandong Zhongyi Zazhi. 2003;22:381-383.  [PubMed]  [DOI]  [Cited in This Article: ]
5.  Deng C, Luo WS. Research progress of healing quality of peptic ulcer with Chinese medicine. Guangxi Zhongyiyao. 2003;26:1-3.  [PubMed]  [DOI]  [Cited in This Article: ]
6.  Qu ZW, Zhang DJ, Liu YP. Protective effect of weiyanling on gastric mucosa of rats. Zhongguo Zhongxiyi Jiehe Xiaohua Zazhi. 2003;11:276-276.  [PubMed]  [DOI]  [Cited in This Article: ]
7.  Li J, Tang FA. Evaluation of clinical application of gastroduodcnal mucosal protutive agcnts. Zhongguo Yiyuan Yongyao Pingjia Yu Fenxi. 2003;3:133-137.  [PubMed]  [DOI]  [Cited in This Article: ]
8.  Qi HJ, Hu MQ, Sun GJ. Experimental research of Chinese medicine on protective effect of gastric mucosa. J Southcast Univ. 2003;22:129-132.  [PubMed]  [DOI]  [Cited in This Article: ]
9.  Fan Q, Fan TY, Jia CR, Den LQ. Protective effect of WK granule on gastric mucosa of rats. Zhongguo Zhongxiyi Jiehe Xiaohua Zazhi. 2001;9:223.  [PubMed]  [DOI]  [Cited in This Article: ]
10.  Zhang WN, Li JB, Wang X. Clinical Study on Jianweiyuyang Granules for Treating the Relapse of Peptic Ulcer. Hunan Zhongyiyao Daobao. 2003;9:15-16.  [PubMed]  [DOI]  [Cited in This Article: ]
11.  Xia JQ, Jia XB, Shen MQ, Xi ZH, Wang DM. Clinical research of preventive recurrence effect of weiyangping granule on peptic ulcer. Zhongguo Zhongxiyi Jiehe Xiaohua Zazhi. 2003;11:229-230.  [PubMed]  [DOI]  [Cited in This Article: ]
12.  Wang B, Yao BT, Wu M. Research progress of preventive recurrence effect of traditional Chinese medicine on peptic ulcer. Jilin Zhongyiyao. 2003;23:51-53.  [PubMed]  [DOI]  [Cited in This Article: ]
13.  Zheng Y, Hua H, Han HG, Song XM. Regulating effect of pugongying capsule for peripheral circulation T lymphocyte subpopulation and preventive recurrence effect on peptic ulcer. Gansu Zhongyi Xueyuan Xuebao. 2003;20:14-15.  [PubMed]  [DOI]  [Cited in This Article: ]
14.  Yang XS, Li YN, Ye CM, Dong XY. Experimental study of correlation of gastric ulcer healing quality with risistance to reinjury by prednisone in rats. Beijing Yike Daxue Xuebao. 1996;28:454-456.  [PubMed]  [DOI]  [Cited in This Article: ]
15.  Shen YG, Liu JC, Chen SB. Etiological and pharmacological treatment of peptic ulcer. Zhongguo Xinyao Yu Linchuang Zazhi. 2003;22:620-624.  [PubMed]  [DOI]  [Cited in This Article: ]
16.  Li G, Wang JZ, Jiu FX. Research progress of therapeutic mechanism on traditional Chinese medicine for peptic ulcer. Hebei Zhongyi. 2003;25:391-392.  [PubMed]  [DOI]  [Cited in This Article: ]
17.  Zhao Y, Wang QG, Li YH, Niu X, Jia YS, Zhang DM, Zhong XG. Effect of banxiaxiexing decoction and partial ingredient on shape change of peptic ulcer in rats. Zhongguo Zhongyi Jichu Yixue Zazhi. 2003;1:16-20.  [PubMed]  [DOI]  [Cited in This Article: ]
18.  Gao Y, Yu H. Research and application of peptic ulcer treated by yanweikang powder. Zhongyi Yaoxuekan. 2003;21:377-378.  [PubMed]  [DOI]  [Cited in This Article: ]
19.  Dong MG, He SD, Ye XH, Zou ZH. Preventing effect of kangerwei granule on rats with laiboratory gastric ulcer. Zhongguo Zhongxiyi Jiehe Piwei Zazhi. 2003;4:117.  [PubMed]  [DOI]  [Cited in This Article: ]
20.  Wang JW, Qu L, Cheng R, Guo LJ. Pharmacological effect of weikexing capsual in the treatment of peptic ulcer. Zhongguo Zhongxiyi Jiehe Xiaohua Zazhi. 2003;11:30-32.  [PubMed]  [DOI]  [Cited in This Article: ]
21.  Zhan XB, Li ZS, Cui ZM, Duan YM, Nie SN, Liu J, Xu GM. Changes of rat gastric mucosal barrier under stress conditions. Zhonghua Neike Zazhi. 2002;41:374-377.  [PubMed]  [DOI]  [Cited in This Article: ]
22.  Li G, Wang JZ, Jiang FB, Li SM. Relationship of platelet active factor, tumor necrosia-a, epidermal growth factor, prostaglandin E2 and peptic ulcer. Hebei Zhongyi. 2003;25:475-477.  [PubMed]  [DOI]  [Cited in This Article: ]
23.  Hu YT, Zhen CE, Xing GZ, Zhang ML, Zhang JS, Wang DX, Lu YM. Relationship of transformation growth factor-alpha, epidermal growth factor, prostaglandin E2 in peptic ulcer patients. Shijie Huaren Xiaohua Zazhi. 2002;10:43-47.  [PubMed]  [DOI]  [Cited in This Article: ]
24.  He JH, Luo HS. Effect of growth factor for healing of peptic ulcer. Guowai Yixue Xiaohua xi Jibin Fence. 2003;1:12-15.  [PubMed]  [DOI]  [Cited in This Article: ]
25.  Wang FW, Li J, Hu ZL, Xie YY. Preventive effect of exogenetic nitride oxide on gastric movement in rat irritable gastric mucosa injury. Shijie Huaren Xiaohua Zazhi. 2003;12:2036-2038.  [PubMed]  [DOI]  [Cited in This Article: ]
26.  Liu XY, Zhou ZG. Influence of yuyang powder on nitride oxide and prostacycli of rats with gastric ulcer by acetic acid. Jiangxi Zhongyi Xueyuan Xuebao. 2003;15:68-69.  [PubMed]  [DOI]  [Cited in This Article: ]
27.  Yu Y, Huo XH. The function of nitride oxide in the cause injury of gastric and intestinal mucosa. Weichangbingxue He Ganbingxue Zazhi. 1997;6:376-378.  [PubMed]  [DOI]  [Cited in This Article: ]
28.  Duan YM, Li ZS, Zhan XB, Gong YF, Xu GM. Protective effect of endothelin-1 specific antibody on irritable gastric mucosa injury. Shijie Huaren Xiaohua Zazhi. 2003;11:990-993.  [PubMed]  [DOI]  [Cited in This Article: ]
29.  Cheng S, Xiao FY, Li GC, Zhang LH. Effect of XiaoKuiLing on endothelin and epidermal growth fastor receptor in rats with acetic gastric uleer. Zhejian Zhongxiyi Jihe Zazhi. 2003;3:4-6.  [PubMed]  [DOI]  [Cited in This Article: ]
30.  Zhang GF, Chen YR, Zhang MX. Relationship between nitride oxide, epidermal growth factor and the injury of gastric mucosa. Weichangbingxue He Ganbingxue Zazhi. 1999;8:293-296.  [PubMed]  [DOI]  [Cited in This Article: ]
31.  He YY, He ZF. 45 Patients with peptic ulcer treated by huangqijiangzhong decoction. Nanhua Daxue Xuebao Yixueban. 2003;31:234.  [PubMed]  [DOI]  [Cited in This Article: ]
32.  Ping ZKS, Du X. Antibacterial effect of huanglianjiedu decoction on Helicobactor pylori. Guowai Yixue Zhongyi Zhongyao Fenche. 2003;25:97-98.  [PubMed]  [DOI]  [Cited in This Article: ]
33.  Zhang B, Cai MQ, Yu M, Liu YJ, Zhang WY. Clinical observation of replenishing qi and dissipate blood stasis on 48 patients with peptic ulcer. Zhongguo Zhonyi Jizheng. 2003;2:22.  [PubMed]  [DOI]  [Cited in This Article: ]
34.  Zheng Y. Regulating effect of pugongying capsule for peripheral circulation T lymphocyte subpopulation and preventive recurrence effect on peptic ulcer. Zhongguo Zhongyiyao Xinxi Zazhi. 2003;10:14-15.  [PubMed]  [DOI]  [Cited in This Article: ]